Exploring Optimal Combinations within Vertical & Parallel Pathways to Clinically Target NSCLC & Beyond
Time: 8:30 am
day: Workshop B
Details:
The validation and clinical progression of novel agents targeting critical nodes in vertical and parallel signaling pathways are crucial to address adaptive and acquired resistance. However, informing disease-specific combination regimens for NSCLC and other RAS pathway-driven malignancies is no easy feat, with challenges surrounding synergistic drug design, cancer histotypes, and diverse patient profiles. This workshop will review the latest developments in targeting the RAS/MAPK pathway, parallel signaling cascades, address concerns for treating diverse oncology landscapes, and provide a clinical update on synergistic agents to help de-risk future combination regimes.
This workshop will discuss:
• Novel agents/approaches to target critical nodes in the vertical RAS/MAPK pathway and parallel signaling pathways to address adaptive and acquired resistance
• Disease-specific approaches/concerns for targeting NSCLC and additional RAS pathway-driven tumor types
• Translation from pre-clinical to clinical studies and update on new clinical data
